Navigation Links
Apnex Medical, Inc. Receives FDA Approval for Pivotal Clinical Study for Obstructive Sleep Apnea

ST. PAUL, Minn., Aug. 2, 2011 /PRNewswire/ -- Apnex Medical, Inc., received investigational device exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to begin a clinical study to evaluate the safety and effectiveness of its Hypoglossal Nerve Stimulation (HGNS®) System to treat obstructive sleep apnea (OSA). Data from this clinical study are intended to support the Pre-Market Approval (PMA) application for the HGNS System to the FDA.

"Many patients who suffer from OSA are unable to tolerate existing therapies such as continuous positive airway pressure (CPAP). The HGNS System provides a fundamentally new approach to the treatment of OSA. This study will help us further understand the potential role this device will have in treating the millions of people who suffer from OSA," said the study's co-principal investigator, Dr. Atul Malhotra, Clinical Chief, Division of Sleep Medicine, Brigham and Women's Hospital.

Sponsored by Apnex Medical, the Apnex Clinical Study is a prospective, randomized, multi-center clinical trial. It is being conducted in leading medical centers in the United States, Europe and Australia. The trial is designed to demonstrate the safety and effectiveness of the HGNS therapy in treating patients with moderate to severe OSA. To be enrolled in the study patients must not have received lasting benefit from CPAP or other OSA treatments.

"We have seen very encouraging results from the HGNS feasibility studies. Results recently presented at the international SLEEP meeting showed that most patients treated with the HGNS System experienced significant improvements in their sleep apnea, sleepiness, and quality of life. This study will help us determine if these results can be demonstrated in a second larger patient population," said the study's co-principal investigator, Dr. Eric Kezirian, Department of Otolaryngology – Head and Neck Surgery, University of California, San Francisco.

About Apnex Medical, Inc. and HGNS System

Apnex Medical was founded in 2006 with a mission to pioneer medical innovations to improve the health of people with sleep disordered breathing. The company has developed a proprietary medical device for the treatment of OSA.

The Apnex HGNS System is an implantable therapy that is intended to work by activating the muscles in the upper airway to ensure that the airway remains open during sleep. The system detects the patient's breathing and delivers mild stimulation to the hypoglossal nerve, the nerve that controls the muscles of the tongue, to keep the airway open. The stimulation is timed to a patient's own breathing pattern. The HGNS System is designed to work only when the patient is asleep through a handheld controller.

About OSA

According to the World Health Organization approximately 100 million people worldwide have OSA. It occurs because of blockage of breathing during sleep. This can deprive OSA sufferers of deep restful sleep and lead to sleepiness and fatigue. OSA sufferers are also at an increased risk for a variety of health conditions, including high blood pressure, coronary artery disease, diabetes and stroke. Untreated OSA is also associated with an increased risk of death. Current OSA treatments are not always successful or well tolerated. The Apnex device is designed to provide an alternative treatment for OSA that addresses these problems.

More information on the Apnex Clinical Study can be found at To learn if you might qualify for the study go to this website or call 1-888-975-3370.

To request additional information, please contact:

Apnex Medical, Inc.
2890 Centre Pointe Drive
St. Paul, MN 55113 USA

CAUTION: The Apnex HGNS System is an investigational device and is limited by Federal Law to investigational use.


Apnex Medical, Apnex and HGNS are registered trademarks of Apnex Medical, Inc.

© Apnex Medical, Inc. 2011 All rights reserved.

SOURCE Apnex Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Apnex Medical, Inc. Raises Additional $14 Million
2. Apnex Medical, Inc. Names Chas McKhann President, Chief Executive Officer
3. Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
4. Prescient Medical, Inc. Achieves Successful Clinical Debut of vProtect(TM) Luminal Shield
5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
6. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
7. New Study Shows that Prebiotics, as Used by Jackson GI Medical, Increases Lifespan by 33%
8. Luminous Medical, Inc. Secures Exclusive Rights to Glucose Sensor for Its Automated Glucose Monitor
9. Cardiva Medical, Inc. Announces the Departure of its President and his Appointment as CEO of Innovative Energy, Inc.
10. Tenaxis Medical, Inc. Announces Completion of the Enrollment Phase of Their Pivotal Study
11. China Sky One Medical, Inc. Completes and Moves into New Corporate Headquarters
Post Your Comments:
(Date:12/1/2015)... 2015 Pharma Tech Outlook recently conducted a ... Data Management Solution Providers - 2015 .  After careful ... CEOs, CIOs, VCs, analysts, and the Pharma Tech Outlook ... top 10 clinical data management solution providers (check out ... and 36 respectively). --> ...
(Date:12/1/2015)... , 1 de diciembre de 2015 ... tecnología para cuchillas de precisión, develó hoy ... de identidad de marca. El nuevo logo ... diseño y la ingeniería de productos con ... diferencia". ...
(Date:12/1/2015)... -- Six months of adjunctive metformin therapy does not improve glycemic ... new research from T1D Exchange and funded by ... effect on measures of obesity, including weight and BMI. The ... of the American Medical Association , are from the largest ... overweight and obese adolescents with type 1 diabetes. ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... , ... Florida Hospital Tampa is the first health care provider in the region ... , vBloc® Therapy is a vagal blocking therapy, delivered via the Maestro® System, for the ... (BMI) of at least 40 to 45 kg, or a BMI of at least 35 ...
(Date:12/1/2015)... ... , ... Dr. Paul Vitenas, one of the top cosmetic surgeons in ... as the Best Single Physician Practice in the nation. Dr. Vitenas and his practice ... by the industry publication. , Dr. Vitenas said he was very honored to ...
(Date:12/1/2015)... ... 01, 2015 , ... CloudLIMS today announced that it is ... under the New Products and Services category for its innovative product offering, BioTracer. ... that helps labs organize data and track samples with storage inventories. BioTracer's ...
(Date:12/1/2015)... ... December 01, 2015 , ... For ... mark the film for accurate interpretation by the radiologist. The marking utensils are ... from Sacramento, Calif., has found a way to alleviate this problem. , He ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... announced it has been awarded a fixed price per sprint agile development contract ... valued at $34 million over five years, provides software engineering, infrastructure, as well ...
Breaking Medicine News(10 mins):